Sina Danesh, Fazal Khan, Trevor Chopko, Aurora Lee, Ran Huo, Shuyang Lu, Vincy Tam, Pedro Fincatto Safi, Wenbin Gao, Austin Todd, Francis D Pagani, Joseph J Maleszewski, Hartzell Schaff, Paul A Friedman, Hakan Oral, Marco Metra, Bertram Pitt, Ienglam Lei, Paul C Tang
{"title":"Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post-Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest.","authors":"Sina Danesh, Fazal Khan, Trevor Chopko, Aurora Lee, Ran Huo, Shuyang Lu, Vincy Tam, Pedro Fincatto Safi, Wenbin Gao, Austin Todd, Francis D Pagani, Joseph J Maleszewski, Hartzell Schaff, Paul A Friedman, Hakan Oral, Marco Metra, Bertram Pitt, Ienglam Lei, Paul C Tang","doi":"10.1101/2025.02.24.639999","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>New postoperative atrial fibrillation (POAF) occurs in about 40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden. We examined the impact of preoperative MRA use on POAF and also examine the atrial cell type impacted by MRA treatment during cold cardiac preservation.</p><p><strong>Methods: </strong>Retrospective study of 19,042 patients who underwent cardiac surgery at Mayo Clinic in Minnesota, and performed 1:3 propensity matching to obtain 298 patients on preoperative MRA matched to 894 who were not. We also separately matched patients using preoperative diuretics. Single-nuclei RNA sequencing (snRNA-seq) examined MRA's effects on different atrial cell types in canrenone (water soluble MRA) treated human donor hearts undergoing cold preservation followed by ex-vivo reperfusion and compared gene expression to the atria of patients with AF.</p><p><strong>Results: </strong>Propensity matched preoperative MRA group had less new onset POAF (19.8% vs 31.5%, P<0.001). To account for the possibility that preoperative diuretic use and volume reduction may impact POAF, we propensity matched 298 preop diuretic users that included MRA use to another 894 patients who used a non-MRA diuretic preoperatively. Those who used preoperative MRA similarly had a lower incidence of POAF (19.8% vs 33.2%, P<0.001). No survival difference was present between the propensity matched groups that used preoperative diuretics (P=0.079). Preoperative MRA use also reduced the development of paroxysmal and chronic AF at 6 years of follow up. From our snRNA-seq data, we identified a subpopulation of atrial cardiomyocytes (CM2) that had high MR expression where canrenone suppressed the increase in MR target gene expression associated with cold preservation-reperfusion. These MR targets were conversely elevated in patients with chronic AF. Canrenone also suppressed other cardiac preservation associated genes that show elevated expression in atrial macrophages and pericytes from chronic AF atria.</p><p><strong>Conclusions: </strong>Our studies show that preoperative MRA use is associated with 40% reduction in POAF as well as lowering long standing AF development by about 41%. Our cold cadiac preservation-reperfusion model showed that canrenone reduced expression of MR target genes associated with chronic AF, particular in cardiomyocytes with important roles in electrical conduction.</p><p><strong>Clinical perspective: </strong><b>What is New?:</b> This study shows that preoperative use of mineralocorticoid receptors antagonists (MRA) is associated with a reduced incidence of new onset perioperative atrial fibrillation after cardiac surgery utilizing cardiopulmonary bypass.We show that preoperative MRA use is associated with a lower incidence of developing more chronic paroxymal or sustained atrial fibrillation.Addition of canrenone, a clinically utilized water soluble MRA, to cardioplegia solution used during cardiac preservation can attenuate atrial inflammatory reponses and reduce signaling through molecular pathways that promote atrial fibrillation.<b>What are the clinical implications?:</b> Perioperative use of MRAs may be considered to reduce early postoperative atrial fibrillation as well as lowering the risk of developing more chronic atrial arrhythmias.These findings support pursuing a clinical trial to determine the impact of MRA use on atrial arrhythmias following cardiac surgery in the setting of cardiopulmonary bypass with cold cardiac preservation.</p>","PeriodicalId":519960,"journal":{"name":"bioRxiv : the preprint server for biology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888355/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"bioRxiv : the preprint server for biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2025.02.24.639999","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: New postoperative atrial fibrillation (POAF) occurs in about 40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden. We examined the impact of preoperative MRA use on POAF and also examine the atrial cell type impacted by MRA treatment during cold cardiac preservation.
Methods: Retrospective study of 19,042 patients who underwent cardiac surgery at Mayo Clinic in Minnesota, and performed 1:3 propensity matching to obtain 298 patients on preoperative MRA matched to 894 who were not. We also separately matched patients using preoperative diuretics. Single-nuclei RNA sequencing (snRNA-seq) examined MRA's effects on different atrial cell types in canrenone (water soluble MRA) treated human donor hearts undergoing cold preservation followed by ex-vivo reperfusion and compared gene expression to the atria of patients with AF.
Results: Propensity matched preoperative MRA group had less new onset POAF (19.8% vs 31.5%, P<0.001). To account for the possibility that preoperative diuretic use and volume reduction may impact POAF, we propensity matched 298 preop diuretic users that included MRA use to another 894 patients who used a non-MRA diuretic preoperatively. Those who used preoperative MRA similarly had a lower incidence of POAF (19.8% vs 33.2%, P<0.001). No survival difference was present between the propensity matched groups that used preoperative diuretics (P=0.079). Preoperative MRA use also reduced the development of paroxysmal and chronic AF at 6 years of follow up. From our snRNA-seq data, we identified a subpopulation of atrial cardiomyocytes (CM2) that had high MR expression where canrenone suppressed the increase in MR target gene expression associated with cold preservation-reperfusion. These MR targets were conversely elevated in patients with chronic AF. Canrenone also suppressed other cardiac preservation associated genes that show elevated expression in atrial macrophages and pericytes from chronic AF atria.
Conclusions: Our studies show that preoperative MRA use is associated with 40% reduction in POAF as well as lowering long standing AF development by about 41%. Our cold cadiac preservation-reperfusion model showed that canrenone reduced expression of MR target genes associated with chronic AF, particular in cardiomyocytes with important roles in electrical conduction.
Clinical perspective: What is New?: This study shows that preoperative use of mineralocorticoid receptors antagonists (MRA) is associated with a reduced incidence of new onset perioperative atrial fibrillation after cardiac surgery utilizing cardiopulmonary bypass.We show that preoperative MRA use is associated with a lower incidence of developing more chronic paroxymal or sustained atrial fibrillation.Addition of canrenone, a clinically utilized water soluble MRA, to cardioplegia solution used during cardiac preservation can attenuate atrial inflammatory reponses and reduce signaling through molecular pathways that promote atrial fibrillation.What are the clinical implications?: Perioperative use of MRAs may be considered to reduce early postoperative atrial fibrillation as well as lowering the risk of developing more chronic atrial arrhythmias.These findings support pursuing a clinical trial to determine the impact of MRA use on atrial arrhythmias following cardiac surgery in the setting of cardiopulmonary bypass with cold cardiac preservation.
背景:心脏手术后新的术后心房颤动(POAF)发生率约为40%。已知矿化皮质激素受体拮抗剂(MRA)可减少慢性心房颤动(AF)的发展和负担。我们检查了术前MRA使用对POAF的影响,并检查了冷心脏保存期间MRA治疗对心房细胞类型的影响。方法:回顾性研究19042例在明尼苏达州梅奥诊所接受心脏手术的患者,并进行1:3倾向匹配,获得298例术前MRA与894例未MRA匹配的患者。我们还分别对术前使用利尿剂的患者进行了配对。单核RNA测序(snRNA-seq)检测了水溶性MRA处理的人供体心脏冷保存后再灌注后MRA对不同心房细胞类型的影响,并比较了af患者心房的基因表达。结果:倾向匹配术前MRA组新发POAF发生率较低(19.8% vs 31.5%, p)。我们的研究表明,术前使用MRA可使POAF发生率降低40%,并使长期房颤发生率降低约41%。我们的心脏冷保存-再灌注模型显示,canrenone降低了与慢性房颤相关的MR靶基因的表达,特别是在电传导中起重要作用的心肌细胞中。临床视角:有什么新发现?这项研究表明,术前使用矿皮质激素受体拮抗剂(MRA)与体外循环心脏手术后围手术期新发心房颤动的发生率降低有关。我们发现术前MRA的使用与慢性阵发性或持续性房颤的发生率较低相关。在心脏保存期间使用的心脏停搏液中加入临床使用的水溶性MRA canrenone,可以减轻心房炎症反应,减少促进心房颤动的分子通路信号传导。临床意义是什么?围手术期使用mra可以减少术后早期心房颤动,并降低发生更多慢性心房心律失常的风险。这些发现支持进行一项临床试验,以确定在低温心脏保存的体外循环条件下,MRA对心脏手术后房性心律失常的影响。